Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9015844 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL56398 | 1.00 | — | — | |
| SCHEMBL1470524 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL730035 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL12500356 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL1470503 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL1470569 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL67396 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL2873944 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL514779 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4703026-A1 | METHOD FOR CARBON DIOXIDE CAPTURE | Københavns Universitet (DK) | 2026-03-04 | — | — | EP | disclosed |
| CN-119256041-A | Block copolymer, method for producing block copolymer, insulating material, polyimide, and printed board | 株式会社力森诺科 | 2025-01-03 | — | — | CN | disclosed |
| CN-119137187-A | Polyamide imide and polyamide imide film | 株式会社力森诺科 | 2024-12-13 | — | — | CN | disclosed |
| US-8883746-B2 | α-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredient | SNU R&DB FOUNDATION (KR) | 2014-11-11 | — | — | US | disclosed |
| US-20100104590-A1 | ALPHA-GALACTOSYLCERAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION FOR THE IMMUNE ADJUVANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2010-04-29 | — | — | US | disclosed |
| EP-2102225-A1 | ALPHA-GALACTOSYLCERAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION FOR THE IMMUNE ADJUVANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT | SNU R&DB Foundation (KR) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008082156-A1 | ALPHA-GALACTOSYLCERAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION FOR THE IMMUNE ADJUVANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104590-A1 | ALPHA-GALACTOSYLCERAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION FOR THE IMMUNE ADJUVANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT | GALC, GBA1, IL4 | TSHR 1318/4885THRB 985/4885SMN1; SMN2 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.